HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infection
HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infection
批准号:
9129330
负责人:
Janice J Endsley
金额:
$63.76万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-01 至 2017-08-31
关键词:
AddressAgeAggressive courseAlveolar MacrophagesAminesAnimal ModelAnti-Bacterial AgentsAnti-Retroviral AgentsAntibacterial ResponseAntitubercular AgentsArginineBiological AssayBiological AvailabilityCD4 Positive T LymphocytesCaspase-1Cause of DeathCellsClinicalComplementControlled StudyDataDefectDevelopmentDietDiseaseDrug InteractionsEnvironmentFunctional disorderGranulomatousGrowthHIVHIV-1HIV-2HealthImmuneImmune System DiseasesImmune responseImmunityIn VitroIndividualInfectionInflammationInflammatoryInflammatory ResponseInterferonsInterleukin-1Interleukin-17InterventionKnowledgeLifeLungMalabsorption SyndromesMeasuresMediatingMetabolismModelingMolecularMusMycobacterium tuberculosisNecrosisNeutrophil InfiltrationNitric OxideOutcomePathologyPathway interactionsPersonsPlayPopulationProductionPublic HealthPulmonary PathologyRegimenReporterResearchRiskRoleSerumSignal TransductionSiteSplenocyteStructure of parenchyma of lungT-Cell DepletionT-LymphocyteTNF geneTestingTissuesTuberculosisViralVirus DiseasesVirus ReplicationWorkabstractinganimal imagingarginasebactericidebasechemokinechemotherapyco-infectioncytokinegain of functionhuman diseasehuman subjectimprovedin vivoinhibitor/antagonistinsightmicrobialmouse modelmycobacterialneutrophilnitrosative stressnovelpathogenresearch studyresponserestorationtargeted treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Tuberculosis (TB) is the leading cause of death in people living with HIV infection. An increased risk of TB precedes CD4+ T cell depletion and can continue following restoration of T cells by anti-retroviral (ARV) therapy. Treatment of co-infected persons is challenging due to the aggressive course of both individual diseases; a clinical problem that is further complicated by drug interaction and malabsorption issues when combining ARVs and TB chemotherapy. Addressing these clinical challenges requires a much greater understanding of co-infection pathophysiology. A critical knowledge gap has developed in the field due to the limited availability of animal models that support HIV replication. To address this gap we developed a novel model of TB/HIV in the BLT humanized mouse (HuMouse) that reproduces important pathological and immunological features of human disease. By using our unique animal model, we are now able to study the microbial synergy of HIV-1 and Mycobacterium tuberculosis (Mtb) infection in the lung. As a result, we have identified candidate molecular mechanisms for co-infection synergy in lung Mφ that promote a pro- inflammatory environment and increase mycobacterial proliferation. The objective of this R01 application is to use the new HuMouse model of TB/HIV co-infection to further elucidate the mechanisms whereby HIV infection disrupts the innate immune response of pulmonary Mφ to Mtb. Our hypothesis is that skewed polarization of pulmonary Mφ due to HIV-1 infection drives a hyperinflammatory response to Mtb, which in turn produces neutrophil-mediated lung damage, reduced bacterial clearance, and increased tissue necrosis. We have three aims to test the following individual hypotheses that 1) host Mφ clearance of intracellular Mtb infection is decreased because of competition for L-arginine needed for both nitric oxide synthesis and HIV replication, 2) HIV and Mtb co-infection drive a pro-inflammatory lung environment via inflammasome-dependent activation of IL-1β in host Mφ, and 3) development of a Th17 cell bias due to the pro-inflammatory environment of co-infection leads to IL-17-dependent neutrophil recruitment and damage in the lungs. These aims will be accomplished by using in vivo studies with Mtb/HIV co-infected humanized mice and in vitro mechanistic studies with isolated lung Mφ. The expected outcome of our work is a significant advance in our understanding of how HIV manipulates the host inflammatory response to Mtb to promote aggressive disease. The positive impact of these results will be the identification of new targets to intervene clinically to restore normal host immunity and improve bacterial clearance in millions of HIV-infected people.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Novel Stem Cell Immunotherapy for MDR-Tuberculosis
-
批准号:10418739
-
项目类别:
-
资助金额:$95.94万
-
财政年份:2021
-
负责人:Janice J Endsley
-
依托单位:
Novel Stem Cell Immunotherapy for MDR-Tuberculosis
-
批准号:10640122
-
项目类别:
-
资助金额:$95.94万
-
财政年份:2021
-
负责人:Janice J Endsley
-
依托单位:
C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection
-
批准号:9538016
-
项目类别:
-
资助金额:$74.83万
-
财政年份:2018
-
负责人:Janice J Endsley
-
依托单位:
C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection
-
批准号:10390479
-
项目类别:
-
资助金额:$77.57万
-
财政年份:2018
-
负责人:Janice J Endsley
-
依托单位:
C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection
-
批准号:10092516
-
项目类别:
-
资助金额:$77.57万
-
财政年份:2018
-
负责人:Janice J Endsley
-
依托单位:
C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection
-
批准号:10159205
-
项目类别:
-
资助金额:$77.57万
-
财政年份:2018
-
负责人:Janice J Endsley
-
依托单位:
HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infection
-
批准号:9335956
-
项目类别:
-
资助金额:$70.56万
-
财政年份:2016
-
负责人:Janice J Endsley
-
依托单位:
HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infection
-
批准号:9204582
-
项目类别:
-
资助金额:$71.94万
-
财政年份:2016
-
负责人:Janice J Endsley
-
依托单位:
Self-assembling Peptide Nanomaterials for Eliciting Mucosal CD8+ T cell Immunity
-
批准号:9036015
-
项目类别:
-
资助金额:$22.76万
-
财政年份:2015
-
负责人:Janice J Endsley
-
依托单位:
A Humanized Mouse Model to Study HIV/Mtb Co-infection
-
批准号:7930463
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2010
-
负责人:Janice J Endsley
-
依托单位:
A Humanized Mouse Model to Study HIV/Mtb Co-infection
-
批准号:8046356
-
项目类别:
-
资助金额:$22.72万
-
财政年份:2010
-
负责人:Janice J Endsley
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: